Story

Taysha Gene Therapies Stock Slides on Wider-Than-Expected Q2 Loss

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Taysha Gene Therapies Stock Slides on Wider-Than-Expected Q2 Loss
Text size
Background

Shares of Taysha Gene Therapies (NASDAQ: TSHA) fell more than 7% in morning trading after the company posted a wider-than-expected second-quarter loss. The sell-off was triggered by a significant jump in operating expenses that overshadowed the company's strong cash position and ongoing clinical progress.

Earnings Miss and Widening Losses

Taysha reported a net loss of $46.6 million, or $0.13 per share, for the second quarter. This missed the consensus analyst estimate of a $0.12 loss per share and marked a substantial increase from the $26.9 million net loss, or $0.09 per share, recorded in the same period a year ago.

The accelerating losses were driven by a sharp increase in spending across the company's operations. Key figures from the report include:

  • Research and development (R&D) expenses: Rose to $38.6 million, an increase of $18.5 million year-over-year, due to activities related to its REVEAL and ASPIRE clinical trials.
  • General and administrative (G&A) expenses: Climbed to $12.1 million from $8.6 million in the prior-year quarter, primarily from higher compensation and costs for commercial launch preparations.
Sample IUX Markets – In-articleAd

Market Context and Outlook

The decline in Taysha's stock was company-specific, occurring as the broader S&P 500 and Nasdaq indices both gained during the session. The negative reaction from investors came despite the company's solid financial footing.

Taysha ended the quarter with $455.4 million in cash and cash equivalents, bolstered by $230.0 million in gross proceeds from a follow-on financing in June. While the company noted its TSHA-102 therapy remains well-tolerated in clinical trials, the market's near-term focus has shifted to the pace of cash consumption ahead of anticipated regulatory milestones in 2027.

Read next

More on Stocks
Back to latest news

LATEST